Meningococcal Polysaccharide Vaccine Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is a purified capsular polysaccharide intermediate derived from Neisseria meningitidis serogroups A, C, W135, and Y. The material is released as a bioburden-controlled or sterile lyophilized powder and as a concentrated aqueous bulk for downstream vaccine manufacture. The tablet, capsule, and granule descriptors are not equivalent to licensed oral vaccine presentations; they refer to the solid-state format of the bulk intermediate during formulation screening or to oral feasibility work. Unconjugated meningococcal polysaccharide is an injectable T-cell-independent antigen. Published data for oral efficacy of this unconjugated antigen are limited, and no oral bioavailability claim is made.

No global proprietary model code applies to the base-grade material. The product is specified by serogroup composition, molecular size distribution, O-acetyl content, residual protein, nucleic acid, bacterial endotoxin, sterility, and residual moisture. A manufacturer-specific code is assigned only after lyophilization into a defined container-closure system and after the batch dossier confirms compliance with the injectable grade release panel.

The material is used as the antigen drug substance for injectable meningococcal polysaccharide vaccines and as the starting polysaccharide for activation and conjugation in conjugate vaccine manufacture. For injectable formulation, the powder is reconstituted in phosphate-buffered saline and diluted to the final antigen concentration for sterile filling. The product is not interchangeable with conjugated MenACWY intermediates, whole-cell vaccines, or pneumococcal polysaccharide APIs.

Release Specification Framework for Purified Meningococcal Polysaccharide Bulk

The release specification is aligned with current WHO recommendations for meningococcal polysaccharide and conjugate vaccine production and with applicable European Pharmacopoeia general methods. Identity is confirmed by immunodiffusion or enzyme-linked immunosorbent assay with serogroup-specific antisera. Molecular size distribution is controlled by high-performance size-exclusion chromatography with refractive index detection. The acceptance criterion is expressed as a distribution coefficient relative to a serogroup-specific reference standard. O-acetyl content is measured by the Hestrin colorimetric reaction because de-O-acetylation of group C polysaccharide reduces recognition by serum bactericidal antibodies. Residual protein is determined by the Lowry method or Ph. Eur. 2.5.33. Nucleic acid is assessed by absorbance at 260 nm. Bacterial endotoxin is tested by Ph. Eur. 2.6.14 or USP <85>. Sterility is tested by membrane filtration per Ph. Eur. 2.6.1 or USP <71>.

Serogroup A polysaccharide contains N-acetylmannosamine-1-phosphate repeating units linked by phosphodiester bonds. This phosphodiester backbone is acid-labile. Serogroup C polysaccharide is a homopolymer of α-2,9-linked N-acetylneuraminic acid carrying O-acetyl groups. W135 and Y polysaccharides contain sialic acid alternating with galactose or glucose. These structural differences require serogroup-specific identity testing before pooling. A positive reaction outside the homologous serogroup indicates contamination or batch misassignment.

Depolymerization control is the main processing boundary for this API. For serogroup A, acid-catalysed hydrolysis of the phosphodiester linkage accelerates below pH 6.0. For serogroup C, de-O-acetylation and desialylation can occur under alkaline or high-temperature conditions. During purification, pH is maintained between 6.0 and 7.4, and process temperatures are held below 25 °C except during short controlled precipitation steps. Lyophilization is performed with an annealing step above the freeze-concentrate collapse temperature determined by freeze-drying microscopy. Chamber pressure is held below the critical collapse pressure. Without annealing, production-scale tray dryers show shrinkage and collapse at the bottom of the cake because product resistance slows sublimation. De-O-acetylation of group C polysaccharide follows pseudo-first-order kinetics in dilute acid; the Arrhenius activation energy should be determined for each serogroup because published data vary with counterion and ionic strength.

Commercial-scale purification uses jacketed stainless steel vessels with bottom-mounted low-shear impellers. Transfer lines are operated at minimal shear using positive displacement pumps rather than centrifugal pumps. Cavitation in centrifugal transfer has been observed to shift HPSEC-RI distribution beyond the reference standard limit. Depth filtration through cellulose-based media reduces endotoxin and bioburden before final filtration. For injectable grade, final sterilising filtration through a 0.22 µm polyvinylidene fluoride membrane is performed after bulk formulation. For dry powder intermediates, filtration occurs before lyophilization.

How Does Unconjugated Polysaccharide API Differ from Carrier-Protein Conjugate Intermediates?

The plain polysaccharide API does not contain a carrier protein. In conjugated meningococcal vaccine production, the polysaccharide is first depolymerized and activated with cyanogen bromide or carbodiimide chemistry, then coupled to tetanus toxoid, diphtheria toxoid, or CRM197. The conjugated product requires additional release tests for free saccharide, saccharide-to-protein ratio, and carrier protein integrity. The plain API release panel remains focused on capsular identity, molecular size distribution, O-acetyl content, and residuals. The plain polysaccharide is not interchangeable with a conjugate intermediate in infant immunisation schedules because the plain form induces a T-cell-independent response with poor immunogenicity in children under 2 years of age and lacks a reliable booster response. This is a product-specific distinction, not a statement of clinical superiority.

Relative to Haemophilus influenzae type b polyribosylribitol phosphate, the meningococcal API is more acid-labile in serogroup A and more dependent on O-acetyl integrity in serogroup C. Relative to pneumococcal polysaccharide APIs, the meningococcal product comprises fewer serogroups and is formulated as a tetravalent A/C/W135/Y intermediate. Cross-substitution is not permitted because identity tests are serogroup-specific and the immunological targets are unrelated.

For solid dosage screening, the lyophilized polysaccharide API can be blended with mannitol and microcrystalline cellulose, but direct compression is limited by hygroscopicity and low bulk density. If capsule or granule intermediates are prepared, processing must occur in low-humidity suites with relative humidity below 30% and product temperature below 25 °C. Aqueous granulation is incompatible with the phosphodiester and O-acetyl stability of the antigen. Any oral delivery claim would require an enteric-coated platform and demonstration of antigen uptake at Peyer’s patches. Published data for this specific configuration is limited.

The lyophilized API is stored at −20 °C ± 5 °C in sealed Type I glass vials with bromobutyl rubber stoppers. Repeated freeze-thaw cycles of the aqueous bulk are not recommended because molecular size decreases and O-acetyl content may fall. The material is incompatible with cationic surfactants after final purification, with acidic buffers below pH 6.0, and with oxidising agents. For injectable formulation, phosphate-buffered saline at pH 6.5–7.4 is used. Calcium-containing diluents are avoided to prevent precipitation of phosphate salts.

Compliance for the injectable grade is demonstrated through a dossier referencing current WHO recommendations for meningococcal polysaccharide vaccines and the relevant Ph. Eur. general methods. Because the product title includes oral and tablet designations, the dossier must clearly separate the validated injectable application from any solid oral feasibility work. Release for pharmaceutical use is not granted solely on the basis of dry weight or identity; the full test panel is performed on each batch.